- Prophylactic mastectomy in BRCA carriers from point of view of plastic surgery2018 | Faculty of Medicine in Pilsen
- The issue of BRCA mutations on clinical point of view2016 | Third Faculty of Medicine
- Zárodečná mutace BRCA jako nový léčebný cíl2020 | First Faculty of Medicine
- BRCA-positive ovarian cancer - case report +12020 | Third Faculty of Medicine
- Mutace BRCA jako podmínka pro indikaci cílené léčby karcinomu prsu2019 | First Faculty of Medicine
- Detection and Incidence of Mutations of BRCA 1 Gene in patients with Cancer of the breast and Ovarz.2003 | First Faculty of Medicine
- Land use changes in the inner central-bohemian periphery - Břekova LhotaPublication without faculty affiliation
- The mutation analysis of gene BRCA 1 in families with genetic risk of breast and ovarian carcinoma2000 | First Faculty of Medicine
- PARP inhibitor olaparib great benefit for a defined group of patients with BRCA positive ovarian cancer2019 | Faculty of Medicine in Pilsen
- Satisfaction and overall quality of life in BRCA positive women after prophylactic surgeries2017 | First Faculty of Medicine
- BRCA1 and BRCA: Genetic testing and what next - Commentary2002 | Publication without faculty affiliation
- Hereditary risk of ovarian cancer and its prophylactic measures2018 | Faculty of Medicine in Pilsen
- Ovarian cancer - hereditary disposition2018 | Faculty of Medicine in Pilsen
- Niraparib expands the availability of maintenance therapy in patients with advanced high-grade ovarian cancer2022 | Faculty of Medicine in Pilsen
- Brest cancer2018 | Third Faculty of Medicine
- Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK2011 | Third Faculty of Medicine
- olaparib2017 | First Faculty of Medicine
- Současné indikace k léčbě inhibitory PARP u pacientek s karcinomem ovarií/vejcovodu2022 | First Faculty of Medicine
- Anti-Müllerian hormone – clinical use and future possibilities2023 | First Faculty of Medicine
- Predictive markers in breast cancer2021 | First Faculty of Medicine
- Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene2010 | First Faculty of Medicine
- Can be considered the primary fallopian tube cancer an enigma at the beginning of the third millenium?2013 | Faculty of Medicine in Hradec Králové
- Therapeutic options in patients with early breast cancer2023 | First Faculty of Medicine
- Paraneoplastic hypercalcaemia in a female patient with tumor duplicity of ovarian and breast carcinoma2006 | First Faculty of Medicine
- Hereditary ovarian cancer, controversis in gynecology practice2004 | Publication without faculty affiliation
- PARP inhibitors in the therapy of ovarian cancer2019 | Faculty of Medicine in Pilsen
- Bcr-Abl fusion sequences do not induce immune responses in mice when administeredin mouse polyomavirus based virus-like particles2009 | First Faculty of Medicine, Faculty of Science, Faculty of Mathematics and Physics
- Hereditary breast cancer: genetic etiology and current possibilities of prevention and surgical treatment2018 | Second Faculty of Medicine
- Olaparib v léčbě recidivujícího karcinomu ovaria2019 | First Faculty of Medicine
